Cologuard is becoming the preferred choice for colorectal cancer (CRC) screening for an increasing number of healthcare providers, patients, and payers. Cologuard is well-positioned to improve CRC screening rates and reduce the human costs related to CRC. Cologuard is the only CRC screening solution that combines high sensitivity with high compliance due to its innovative use of stool DNA technology and built-in patient compliance program.
Read Exact Sciences' white paper entitled Cologuard: A Call to Action in Colorectal Cancer Screening, authored by Philip Parks, MD, MPH, FACOEM and Emily Weiser, MPH to learn how:
- Cologuard’s innovative advantages make it an ideal choice for non-invasive CRC screening for providers, patients, and payers
- Cologuard is positioned to address stagnant CRC screening rates, as more than one-third of the country remains unscreened
- Cologuard’s clinical validity and utility provide superior value for detecting CRC and precancerous lesions
Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma (AA) and should be followed by diagnostic colonoscopy. Cologuard is indicated to screen adults of either sex, 50 years or older, who are at typical average-risk for CRC. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high risk individuals.